ArticleMedical oncology (Northwood, London, England)2018

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Hisashi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.